VNDA Vanda Pharmaceuticals Inc.

NASDAQ
$3.75

Vanda Pharmaceuticals Inc. (VNDA) is expected to report earnings on January 27, 2027, after the market close. The consensus earnings estimate is a loss of $0.32 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -15.7% since its last earnings release on October 28, 2026.

Vanda Pharmaceuticals Beat Consensus Estimates, Lowers Guidance In-line with Estimates
Wednesday, October 28, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Jan 27
Wednesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.32)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.89

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders such as HETLIOZ, Fanapt and VLY-686.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.